Date: 30.07.2020

The Deputy Manager Department of Corporate Services Bombay Stock Exchange Limited (BSE) P.J. Towers, 25th Floor, Dalal Street, Fort Mumbai - 400001

The Manager (Listing Department) National Stock Exchange of India Limited (NSE) Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Scrip Code: 526707

Scrip Code: ALCHEM

Sub: Outcome of Board Meeting held on 30th July, 2020

CHEMIST

Dear Sir/Madam,

Pursuant to provision of regulation 30 and 33 and any other applicable provisions, if any of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") the Board of Directors of the Company in its meeting held on Thursday, 30th Day of July, 2020, i.e. today, have inter— alia considered, approved and taken on record the following businesses:—

- 1. Audited Financial Results (Standalone and Consolidated) of the company for the Quarter and Year ended on 31st March, 2020. A copy of the Audited Results for the Quarter and Year ended on 31st March, 2020 as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached.
- Statutory Auditor Report with unmodified opinion of Audited Standalone and Consolidated Financial Results of the company for the Quarter and Year ended on 31st March, 2020. A copy of the Statutory Auditor Report for the Quarter and Year ended on 31st March, 2020, as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached.

You are requested to take the above information on your record & acknowledge the same.

Thanking you

Yours Sincerely

For Alchemist Limited Divya Bajaj Company Secretary

ALCHEMIST LTD.

CIN: L72200DL1988PLC192643

Regd. & Head Office : Alchemist House, Building No. 23, Nehru Place, New Delhi - 110019 Tel. : +91 - 40600800, Fax : +91-40600888 Chd. Office : Plot No. F5, Rajiv Gandhi IT Park, Chandigarh - 160 101 Tel. : +91-172-4266666, Fax: +91-172-4266602 E-mail : investors@alchemist.co.in Website : www.alchemist.co.in

(36.61)	(34.46)	5.48	(1.08)	(29.33)	-Diluted	
(36.51)	(34.46)	5.48	(1.08)	(29.33)	-Basic	
					Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items	14
					(Face Value of ₹ 10/- each per share)	
1355.98	1355.98	1355-98	1355.98	1355.98	Paid up equity share capital	13
(4974.74)	(4665.00)	745.89	(147.04)	(3968.95)	lotal comprehensive income, for the period	12
(10.98)	7.78	3.01	0.00	7.78	i otal Uther comprehensive Income, net of tax	11
3.86	(2.73)	(1.05)		(2.73)	Tax on above	
(14.84)	10.51	4.07	-	10.51	Re-measurement of the net defined benefit plans	
					Items that will not be reclassified to profit or loss	
					Other Comprehensive Income	10
(4963.76)	(4672.78)	742.89	(147.04)	(3976.73)	Profit(+)/ Loss(-) for the period (7-8)	9
(1096.21)	(1125,45)	(1177.36)	(172.14)	(993.30)	b) Deferred Tax	
r	3	,		•	a) Current Tax	
					Tax Expenses	8
(6059.97)	(5798.23)	[434.47]	(319.18)	(4970.03)	Profit Before Tax (5-6)	7
0.00	0.00	0.00	0,00	0.00	Exceptional Items	6
(6059.97)	(5798.23)	(434,47)	(319.18)	(4970.03)	Profit before Exceptional & Extraordinary Items (3-4)	υ,
8825.75	7268.70	1015.31	586.99	5118.69	Total Expenses	
634.92	380,42	184.79	79.46	92.08	(ii) Other Expenditure other than (i) above	
4644.28	4644.28	4		4644.28	(ii) Provision for Expected Credit Loss	
ŀ.,	,	•	f	,	(i) Foreign Exchange (Gain)/Loss	
					g) Other Expenditure	
690.01	664.67	165.61	166.84	162.56	f) Depreciation & Amortisation	
136.91	55.26	29.88	18.85	15.06	e) Finance costs	
738.35	540.78	161.50	130.69	109.87	d) Employees benefit expenses	
24.24	32.95	{61'£}	26'9	1.60	c) (increase)/decrease in stock in trade, finished goods and scrap	
1109.44	481.28	247.54	87.39	11.90	b) Purchase of stock in trade	
847.60	469.07	229.17	96.84	81.34	a) Consumption of Raw Material & Others	
					Expenditure	4
2765.78	1470.47	580.83	267.81	148.55	Total Revenue (1+2)	ω
92.18	29.30	9.14	3.71	20.14	Other Income	2
2673.60	1441.17	571.69	264.11	128.52	Net Sales (Net of Excise Duty) / Incomes from Operations	1
(Audited)	(Audited)	(Refer Note 2)	(Unaudited)	(Refer Note 2)		
31.03.19	31.03.20	31.03.2019	31.12.2019	31.03.2020		
nded	Year Ended		Quarter Ended			
ept EPS data)	(T in Lacs except EPS data)				Particulars	S.No
		ED 31.03.2020	E QUARTER AND YEAR ENDE	NANCIAL RESULTS FOR TH	PART I: STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31	
	o.in	n. Website: www.alchemist.cc	E-mail: info@alchemist.co.li	00. Fax: {91-11} 40600888.	CIN NO.:L72200DL1988PLC192643. Tei No.: (91-11) 40600800. Fax: (91-11) 40600888. E-mail: info@alchemist.co.in. Website: www.alchemist.co.in	
			DELHI-110 019	REGD.OFFICE : 23 NEHRU PLACE, NEW DELHI-110 019	REGD.OFFIC	
				ALCHEMIST LIMITED		

e

Ì

	b) Agri Business	a) Pharma	(Segment a	5 Capital Employed	 Total Liabilities	b) Agri Bu	a) Pharma	4 Segment Liabilities	Total Assets	b) Agri Business	a) Pharma	3 Segment Assets		Castell to fait offer Tay	Correct and Do	Total Profit before Tax	Less: Exceptional Item	Add: Other Incomes	Less: Financial Charges	Total	b) Agri Business	a) Pharma	Profit/(Loss) bt	2 Segment Results	Net Sale	Less Intu	Sub-Total	b) Agri Business	a) Pharma	1 Segment Revenue (Net)		S.No.			
Total	Isiness	a) Pharma, Chemical & Minerals	(Segment assets-Segment Liabilities)	yed	s	ISINESS	a) Pharma, Chemical & Minerals	lities		Isiness	a) Pharma, Chemical & Minerals	8		ererieu iax ter Tav	aforrod Tax	fore Tax	nai Item	omes	Charges		Isiness	a) Pharma, Chemical & Minerals	Profit/(Loss) before tax and interest from segments)	lts	Net Sales/Incomes	Less Inter Segment Revenue		Isiness	a) Pharma, Chemical & Minerals	anue (Net)		Particulars			PARTII: SEGMENTI
24914.78	787.27	24127.51			 14849.25	142.49	14706.76		39764.03	929.76	38834.27		101101	12076 731	(06 200)	(4970.03)	-	20.14	15.06	(4975.11)	69.26	(5044.37)			128.52	-	128.52	127.82	0.70		31.03.2020				PART II: SEGMENT INFORMATION FOR THE QUARTER AND YEAR ENDED 31.03.2020
79682.04	752.12	28929.92		-	14975.14	156.69	14818.45	*****	44657.18	908.81	43748.37		()	(M 211]	1170 111	(319.18)	-	3.71	18.85	(304.03)	(95.27)	(208.76)			264.12		264.12	143.10	121.01		31.12.2019	Quarter Ended			AND YEAR ENDED 31.03.202
20072 EA	799.95	29073.55			14765.01	159.11	14605.91		44638.51	959.06	43679.46			108 CVL	11177 361	(434,47)		9.14	29.88	(413.73)	64.04	(477.77)			571.69		571.69	267.61	304.09		31,03.2019		STANDALONE		a
7491 <i>4</i> 78	787.27	24127.51			 14849.25	142,49	14706.76		39764.03	929,76	38834.27		((21 3611)		•	29.30	55.26	(5772.27)	(209.86)				1441.17	•	1441.17	699.01	742.16		31.03.20	Year Ended		,₹ in Lacs)	
24823 20	799.95	29073.55			14765.01	159.11	14605.91		44638.51	959.06	43679.46			(137 23PV)	11/06 211	(6059.97)	1	92.18	136.91	(6015.24)	(242.99)	(5772.25)			2673.60	ł	2673.60	1122.03	1551.58		31.03.19	ded		{ s	

Place: New Delhí Date: 양 507/2020		8) Th	7) Th 20 liai	5) Th rec los gra fin	5) Th No	4) a a pa ac	3) Th	2) TF 3J	1) 17 m
- Whole ONA CO	By Order of Board For Alchemist Limited	The Company has not carried out the impact assessment study that COVID- 19 may have on its operations and financials.	The income tax department has through its order dated 7th February, 2019 has demanded an amount of ₹ 29,129.34 Lakhs in lieu of the assessment carried out by the income tax departments for the assessments years 2009-10 to 2015-16. The Company has not provided for such liability in its books as it has appealed against such demand raised by the income tax department. The liability however, has been reflected as a contingent liability.	The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company has recently even closed down its loss making pharmaceutical manufacturing. The units of the company now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The Company can even liquidate its non-core strong fixed assets cover to support the operations in times of any need. Further, the Company has the backing of the strong group because of which the Company has been able to pay off its borrowings from Punjab National Bank and support the operations of the Company whas incurred losses in the recent past. The financial statements, as such have been prepared on a going concern basis.	The working capital limits of ₹ 350.00 Lakhs availed from Bank of India for the working capital requirements of the pharmaceutical division has been classified as non performing asset (herein referred to as 'NPA') on 30th November, 2018. The outstanding as on the date of classification by the bank as NPA was Rs. ₹ 363.88 Lakhs. The Company has not recognised interest liability on such loan from the day it has become NPA, in line with the practice followed by the respective bank.	The company extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 takhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Company is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, still considering the principal of conservatism, the Company has made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealized foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2019-20. Hence forth, the Company has counting for the unrealised foreign exchange loss on such export receivables and the same will only be accounted for on actual realisation/payment. Cumulatively, the provision for expected credit loss on such export receivables stands at ₹ 9,288.56 Lakhs.	The figures for the previous period have been regrouped/reclassified, wherever necessary to conform to the current period's presentation.	The figure for the quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figure of the years ended 31st March, 2020 and 31st March, 2019 respectively and published financial results of nine months ended 31st December, 2019 and 31st December, 2018 respectively.	The above standalone financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 28th July, 2020. The Statutory Auditors have expressed modified opinion on these results.

. .

Interface Note of the second memory between the second m	STANDALORS STRET ANALY. STRET Control of the interplant Ander Former Name Kan of the interplant Ander Former Name Station Kan of the interplant Ander Former Name Station Kan of the interplant Ander Former Name Station Station Station Other Interplant Ander Former Name Station Station Other Interplant Ander Former Name Station Station Conserver Former Name Station Station Conserver Former Name Station Station	Bikram Bhattacharya (Whole Time Director) Din 03595530		Place: New Delhi Date: 곳 % 07.2020	
Ases Property, Part Ases Instances (and Support Unit Instances (and Support Instances (a	STANOACCI STREET KAR 11 2010 (Colspan="2") Nome Kar 110 Kar 11	By Order of Board For Alchemist Limited			
Arest Nor-Current Jabilities (before that is all entry its association of the set of the set of the property. Plant of feators interview interv	STANDAGONE BALAVES SHEET IS SAT 21 "March, 2020 (Intermit and the set of the se	1000 1000 1000 1000 1000 1000 1000 100			
Arrest Non-Current Asses Francial Asset Francial Asset Francinal Asset Francial Asset Francial Asset Francial Asset Fr	STANDAGONE BALAVIES SHEET KS KAT Shi Markh, 2000 (Intel (Intel (Intel March, 2000 (Intel Kates)	16433119	15118.11	Total Current Liabilities	
Ares Kar st 1 ⁴ March, 2020	STANDAGONE BALAVIES SHEET KSAT 21 'Watch, 2020 (Intel Intel In	203.91	249.08	Other current liabilities	
Arest Nor Current Assets Kar st 31" Name, 2020 Kar st 15" Name, Strandal Assets Strandal Assets Strandal Assets 1 3340.05 (2016) 1 3340.35 (2017) 1 3350.35 (2017)	Standardov Kristin Kancis van di sublicità Karis 1º Marci, 2001 Landia <	13187.62		small enterprises Other financial liabilities	
Ansa Kantholity Kantholity <td>STANUATIONE BALANCE SETER SATE IN ANALY, 2007 (Intel Asset (Intel) Assets Sandon Sandon Property, Fair and Fairpines Sandon I Property, Fair and Fairpines I Sandon I Uncertified tax serves (tel) I Sandon I I Other Non-current Assets I I I I Current Assets (tel) I I I I Other Non-current Assets I I I I Carrent Assets (tel) I I I I Defined Invest Carlet IIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII</td> <td></td> <td></td> <td>Total outstanding dues of micro enterprises and small enterpr Total outstanding dues of creditors other than micro enterprises</td>	STANUATIONE BALANCE SETER SATE IN ANALY, 2007 (Intel Asset (Intel) Assets Sandon Sandon Property, Fair and Fairpines Sandon I Property, Fair and Fairpines I Sandon I Uncertified tax serves (tel) I Sandon I I Other Non-current Assets I I I I Current Assets (tel) I I I I Other Non-current Assets I I I I Carrent Assets (tel) I I I I Defined Invest Carlet IIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII			Total outstanding dues of micro enterprises and small enterpr Total outstanding dues of creditors other than micro enterprises	
Ansa Kat strift March, 2001 Ling L	STAUDATIONE BIAJANCE STRET KS AT 31' March, 2001 (Inc) Kin K	407.68	375.07	Financial Liabilities Borrowings	
Astro Kastri March, 200 Link Link <thlink< th=""></thlink<>	STANDAUCCE SHEET KS AT 31 'March, 200 R nucl R nucl <thr< td=""><td>75936.71</td><td>76756.45</td><td>Total Non - Current Liabilities Current liabilities</td></thr<>	75936.71	76756.45	Total Non - Current Liabilities Current liabilities	
Astro Kart (minute) Astronomic Statif Mon - Current Assets Statif Francial Assets 13340.35 Current Assets 13340.35 Francial Assets 1335.35 Francial Assets 1350.35 Francial Assets 1350.35 Francial	STANDADONE BAJANCE SHEET JAS AT 217 March, 200 (minut) (minut) (minut) More (minut) More (minut) (minut) (minut) More Current Assets (assets (net) (assets (net) (assets (net) (assets (net) (assets (net) (assets (net) (asset (net) <th c<="" td=""><td></td><td>20,00</td><td>Deferred Tax Liabilities (Net)</td></th>	<td></td> <td>20,00</td> <td>Deferred Tax Liabilities (Net)</td>		20,00	Deferred Tax Liabilities (Net)
Assets Ke at 21 th March, 2020 Ke at 21 th March, 2020 Standborg Assets Standborg Standborg 1 Property, Plant and Equipment 1330.05 1330.05 1 Deferred Tax sees: (net) 1330.05 1330.05 1 Other Non-Current Assets 1330.05 1330.05 1 Total Non-Current Assets 1330.05 1 1 Other Non-Current Assets 1330.05 1 1 Total Non-Current Assets 1330.05 1 1 Total Non-Current Assets 1330.05 1 1 1 Total Non-Current Assets 1330.05 1 <	STANUCIONE BALANCE SUEET AS AT 31" March, 2020 (En ruad) (En ruad) </td <td>371.34 371.34</td> <td>411.39</td> <td>Other Financial Liabilities</td>	371.34 371.34	411.39	Other Financial Liabilities	
Agests Age at 31" March, 2000 (K mLst) Agests Kar at 5 (nument) Standalone Kar at 31" March, 2000	STANDAUCY: DIALANCE: SHEEP, ASS AT 32' MARCH, 2020 (Fin last (Fin last (Fin last Assets (Fin last Poperty, Pint and Equipment (Sin 2330.95 (Fin last Poperty, Pint and Equipment (Sin 2330.95		2C 00C3C	Financial Liabilities	
Asts Ast 31" March, 2020 Kan Clip Asts Sandalone Sandalone Property, Plant and Equipment Sandalone 1 Other Intangible Assets 13340,95 1 Investments 13340,95 1 Defaund Assets 13340,95 1 Other Non-Cirrent Assets 13340,95 1 Contrast Assets 13340,95 1 Other Non-Cirrent Assets 13340,95 1 Contrast Assets 13340,95 1 1 Contrast Assets 13340,95 13340,95 1 Contrast Assets 13340,95 13340,95 1 Contrast Assets 1325,95 1325,95 1 1 Contrast Assets 1340,97 1 1 1 Contrast Assets 1342,97 1 4 1	STANDALONE DAVANCE SHEEP, ASA 732' MARCH, 2000 (In Las) (In Las) (In Las) Assets Standalore Mon-Current Assets Standalore (In Las) Poperty, Plant and Engineent Standalore (In Las) Other Strandal Assets In ancial Assets Standalore (In Las) Deferred tax asset (arc) Standalore (In Las) (In Current Assets			Liabilities	
Astest No - Current Assets Property, Plant and Equipment Kar 31 ^r March, 7020 Kar 31 ^r March, 7020 <th core="" o<="" of="" td=""><td>STANDALOUE BRAINVERS SHEET, NAX AT 31* WANCH, 2000 K <thk< th=""> K <thk< th=""> K <thk< td=""><td></td><td></td><td>Non- Controlling Interest</td></thk<></thk<></thk<></td></th>	<td>STANDALOUE BRAINVERS SHEET, NAX AT 31* WANCH, 2000 K <thk< th=""> K <thk< th=""> K <thk< td=""><td></td><td></td><td>Non- Controlling Interest</td></thk<></thk<></thk<></td>	STANDALOUE BRAINVERS SHEET, NAX AT 31* WANCH, 2000 K <thk< th=""> K <thk< th=""> K <thk< td=""><td></td><td></td><td>Non- Controlling Interest</td></thk<></thk<></thk<>			Non- Controlling Interest
Asset Karet Name Karet Str Namet, DDD	STANDADORE BALANCE SPIEER AS AT 31" March, 200 (In Las) Arsets (In Las) Arsets Standalore (In Las) Property, Plant and Equipment Standalore (In Las) Other Intanglie Assets Investments 13340.36 (In Las) Deferred Isa assets (In Las) Standalore Investments 13340.36 (In Current Assets Investments 13340.36 Standalore Investments 13340.36 Standalore Investments 13340.36 Standalore Investments 1340.36 Standalore Investments 1340.36 Investments 1340.36 Investments 1340.36 Investments 1340.36 Investments 1350.31 Investments 1350.31 Investments 1350.31 Investments 1350.31 Investments <td></td> <td>(19615:65)</td> <td>Total Equity</td>		(19615:65)	Total Equity	
Asset Kar 31 th March, 2020 Kar 31 th March, 2020 <thk< td=""><td>Assts Standarder Sitter XX AT 312 March, 2020 (7 in Las) Assts Standalone Standalone (7 in Las) Assts Standalone Standalone 1 3340,99 1 3340,99 1 Other Intangible Assets Insertition Standalone 1 1 Investments Insertition Standalone 1 Other Intangible Assets 13340,99 1 1 Investments 13340,99 1 1 Other Intangible Assets 13340,99 1 1 Other Non-Current Assets 13340,99 1 1 Other Non-Current Assets 13340,99 1353,79 1 Inventories 3333,99 1334,79 1 3 Inventories 33,89 1 33,49 3 3 Current Assets (Net) 1,37 1,37 33,49 3 4 Current Assets 33,49 1,37 4 4 4 Current Assets 772,34 1,37 4 4<td>(16306.63)</td><td>(20971.63)</td><td>Other Equity</td></td></thk<>	Assts Standarder Sitter XX AT 312 March, 2020 (7 in Las) Assts Standalone Standalone (7 in Las) Assts Standalone Standalone 1 3340,99 1 3340,99 1 Other Intangible Assets Insertition Standalone 1 1 Investments Insertition Standalone 1 Other Intangible Assets 13340,99 1 1 Investments 13340,99 1 1 Other Intangible Assets 13340,99 1 1 Other Non-Current Assets 13340,99 1 1 Other Non-Current Assets 13340,99 1353,79 1 Inventories 3333,99 1334,79 1 3 Inventories 33,89 1 33,49 3 3 Current Assets (Net) 1,37 1,37 33,49 3 4 Current Assets 33,49 1,37 4 4 4 Current Assets 772,34 1,37 4 4 <td>(16306.63)</td> <td>(20971.63)</td> <td>Other Equity</td>	(16306.63)	(20971.63)	Other Equity	
Asset Non - Current Assets Property, Plant and Equipment Other Intangbie Assets Investments Unextments Kar 31 ^m March, 2020 I <thi< th=""></thi<>	Asset Non-Current Assets Kar 31" March, 2020 Kn 1150 Asset Non-Current Assets 13340,95 13340,95 1 Cher Intangible Assets 13340,95 1 1 Financial Assets 13340,95 1 1 Deformed tax assets (net) 13540,95 1 1 Total Non - Current Assets 13540,77 1 1 Inventories 1554,77 1 1 Inventories 1534,77 1 1 Inventories 1534,77 1 1 Inventories 1534,77 1 1 1 Inventories 1534,77 1 1 1 1 Inventories 1534,77 1	1335 98	1355.98	Equity Share Capital	
Asets Kard 31 ^m March, 7020 Kard 31 ^m March, 7020 <thk< td=""><td>STANDALONCE SPIEER AS AT 31 "MARCH, 2020 C In Lass Assets Ke at 31" March, 2020 Ke at 31" March, 2020 Ke at 31" March, 2020 Assets Non - Current Assets Standalone Ke at 31" March, 2020 Ke at 31" March, 2020 Other Intergible Assets Trancial Assets 13340.95 Standalone 1 Other Intergible Assets Content Assets 13340.95 1 1 Other Intergible Assets 13340.95 1 1 1 Other Intergible Assets 13340.95 1 1 1 Other Intergible Assets 712.04 1 1 1 Other Non-Current Assets 712.04 1 1 1 Other Non-Current Assets 712.04 1 1 1 Other Stand Cash Equivalents 53.81 1 1 1 1 1 Other Stand Cash Equivalents 53.81 1 1 3 3 3 3 4 3 4 3 Other Stand Cash Equivalents 752.34</td><td></td><td></td><td>and Liabilities</td></thk<>	STANDALONCE SPIEER AS AT 31 "MARCH, 2020 C In Lass Assets Ke at 31" March, 2020 Ke at 31" March, 2020 Ke at 31" March, 2020 Assets Non - Current Assets Standalone Ke at 31" March, 2020 Ke at 31" March, 2020 Other Intergible Assets Trancial Assets 13340.95 Standalone 1 Other Intergible Assets Content Assets 13340.95 1 1 Other Intergible Assets 13340.95 1 1 1 Other Intergible Assets 13340.95 1 1 1 Other Intergible Assets 712.04 1 1 1 Other Non-Current Assets 712.04 1 1 1 Other Non-Current Assets 712.04 1 1 1 Other Stand Cash Equivalents 53.81 1 1 1 1 1 Other Stand Cash Equivalents 53.81 1 1 3 3 3 3 4 3 4 3 Other Stand Cash Equivalents 752.34			and Liabilities	
Asets Non-Current Asets Property, Plant and Equipment Other Intangible Asets Financial Assets Ionan Other Non-current Asets Kar 31" March, 2020	Assets Kar 31 ^m March, 2020 K march, 2020 Assets Kar 31 ^m March, 2020 K march, 2020 Non - Current Assets Standone K march, 2020 K march, 2020 Other - Current Assets I and Equipment I 3340.95 I 1340.95 I 1 Other Intergible Assets I 1340.95 I 1340.95 I 1 Other Non-Current Assets I 1340.95 I 1 Other Non-Current Assets I 1340.95 I 1 Other Non-Current Assets I 1334.79 I 1 Other Non-Current Assets I 1334.79 I 1 Deferred Ixa assets (net) I 1334.79 I 1 Tade Receivables I 1334.79 I 1 Current Assets I 1334.79 I 1 Deferred Ixa assets (Net) I 1334.79 I 1 Tade Receivables I 1334.79 I 1 Current Assets I 1334.91 I 1 Deferred Ixa Assets (Net) I 1334.91 I 1 Deferred Ixa Assets I 1334.91 I 1 I 1 Defere Current Assets I 1334.91	77419.25		Tot	
Asets Aset 31 ^T March, 2020 Standalone Assets Property, Plant and Equipment Other Intargible Assets 13340.36 1 Property, Plant and Equipment Others 13340.36 1 1 Deferred tax assets (net) 13850.34 1 1 Other Non-Current Assets 1334.79 1 1 Deferred tax assets (net) 1334.79 1 1 Other Non-Current Assets 1334.79 1 1 Inventories 11.87 1 1 1 Trade Receivables 53.81 1 3411.37 1 34 34 Cheres 53.81 1 </td <td>STANDALIVE BALANCE SPIEE AS AT 31" MARCH, 2000 (* In Lacy) (* In Lacy) Asets Kar 31" March, 2000 Kar 31" March, 2000 Asets Standalone Standalone I Asets Investments 13340.95 I I Charin Assets I I I I Deformed tax assets (net) I I I I I Other Intangible Assets I I I I I Corrent Assets I I I I I I Deformed tax assets (net) I I I I I I Current Assets I I I I I I I Deformed tax assets (net) I I I I I I I Current Assets I I I I I I I I I I I I I I <t< td=""><td>43778.74</td><td>10.000 and 10.000 and 10.000</td><td>Total Current Assets</td></t<></td>	STANDALIVE BALANCE SPIEE AS AT 31" MARCH, 2000 (* In Lacy) (* In Lacy) Asets Kar 31" March, 2000 Kar 31" March, 2000 Asets Standalone Standalone I Asets Investments 13340.95 I I Charin Assets I I I I Deformed tax assets (net) I I I I I Other Intangible Assets I I I I I Corrent Assets I I I I I I Deformed tax assets (net) I I I I I I Current Assets I I I I I I I Deformed tax assets (net) I I I I I I I Current Assets I I I I I I I I I I I I I I <t< td=""><td>43778.74</td><td>10.000 and 10.000 and 10.000</td><td>Total Current Assets</td></t<>	43778.74	10.000 and 10.000	Total Current Assets	
Kerets Saret SI ^T March, 2020 Standaloge Saret SI ^T March, 2020 Saret SI ^T Saret	STANDACINE BALANCE SPIEEr AS AT 31' March, 2020 [C In Lacs] Standacine (In Lacs) Assets Assets Standacine As at 31' March, 2020 [C In Lacs] Non - Current Assets Property, Plant and Equipment Standacine Investments 13340.96 1 Other Intangible Assets Investments 13340.96 Standacine 1 Deferred tax assets (net) 13340.96 13340.96 1 Other Non-current Assets 13340.96 1 1 Deferred tax assets (net) 13340.96 1 1 Other Non-current Assets 13340.96 1 1 Current Assets 13340.96 13340.96 1 Current Assets 13340.96 13340.96 1 Deferred tax assets 13340.96 13340.96 1 Current Assets 13340.96 13340.96 1 Deferred tax assets 3317.37 3317.37 3317.37 3317.37 Deferred tax assets 3339.50 3339.50 3339.50 3349.50 334	0.25	1.87	Current Tax Assets (Net) Other Current Assets	
Kon Series Series <td>STAUCALIONE BALANCE SHEET AS AT 31 MARCH, 2020 C In Lacy Kindeline Assets Assets Non - Current Assets Standalone Property, Plant and Equipment Standalone Other Intangible Assets Investments Investments Standalone Other Intangible Assets Investments Other Intangible Assets Investments Other Intangible Assets Investments Other Intangible Assets Investments Ionan Investments Ionana Investments Other Non-current Assets Investment Sets Investment Sets Standalone Investment Sets Investment Sets Investment Assets Intel Assets Investment Sets Standalone Investment Assets Standalone Investment Assets Intel Assets Investment Sets Intel Assets Investment Sets Standalone Investment Assets Standalone Investment Sets Intel Assets Investment Sets Sta</td> <td>61.22 504-67</td> <td>33.49</td> <td>Others</td>	STAUCALIONE BALANCE SHEET AS AT 31 MARCH, 2020 C In Lacy Kindeline Assets Assets Non - Current Assets Standalone Property, Plant and Equipment Standalone Other Intangible Assets Investments Investments Standalone Other Intangible Assets Investments Other Intangible Assets Investments Other Intangible Assets Investments Other Intangible Assets Investments Ionan Investments Ionana Investments Other Non-current Assets Investment Sets Investment Sets Standalone Investment Sets Investment Sets Investment Assets Intel Assets Investment Sets Standalone Investment Assets Standalone Investment Assets Intel Assets Investment Sets Intel Assets Investment Sets Standalone Investment Assets Standalone Investment Sets Intel Assets Investment Sets Sta	61.22 504-67	33.49	Others	
Kon Standalone Kar 31 ^r March, 2020 Kar 31 ^r March, 2020 Standalone As at 31 ^r March, 2020 Standalone As at 31 ^r March, 2020 Standalone As at 31 ^r March, 2020 Standalone Imarch As at 31 ^r March, 2020 Standalone Imarch Imarch Standalone Imarch Imar	STAUCALIONE BALANCE SHEET AS AT 31 MARCH, 2020 (* In Lac) A sets Assets As at 31** March, 2020 (* In Lac) Assets Standalone 1 Assets Standalone 1 Property, Plant and Equipment 13340.96 1 Other Intangible Assets 13340.96 1 Investments 13340.96 1 Ideans 112.04 13347.97 Deferred tax assets (uet) 712.04 1 Other Non-current Assets 3117.37 1 Inventories 3341.73 33.81 Inventories 33.81 33.81 Inventories 37889.50 33.81 Trade Receivables 37889.50 41 Carent Assets 37889.50 41		12.61	Bank Balances	
Kon Sarst Sarst Sarst Assets Aset 31 ^m March, 2020 Standaone 1 Assets Property, Plant and Equipment 13340.96 1 1 Other Intangible Assets Intarch, 2020 Standaone 1 1 Deberred tax assets (net) 13860.84 13340.96 1 1 Other Non-Current Assets 112.04 1 1 1 Deberred tax assets (net) 1354,79 1 1 1 1 Other Non-Current Assets 1344,79 1	STAUCALIONE BALANCE SHEEF AS AT 31 MARCH, 2020 (E In Lac) (In Lac) Asets Asets Asets Non - Current Assets Francial Assets Sar 31 th March, 2020 As at 31 th March, 2020 Cher Intagible Assets Intractine Intractine Intractine Deferred tax assets (net) 11534.79 11534.79 Intractine Total Non - Current Assets 11534.79 Intractine Intractine Standal Assets 11534.79 Intractine Intractine Standal Assets 11534.79 Intractine Intractine Total Non - Current Assets 11534.79 Intractine Intractine Inventories 11534.79 <t< td=""><td>42544-38 212.14</td><td>37889.60 223.55</td><td>Trade Receivables</td></t<>	42544-38 212.14	37889.60 223.55	Trade Receivables	
Kon Series Series Assets As at 31 ^m March, 2020 Standalone Assets Francial Assets Standalone Property, Plant and Equipment 13340.96 1 Other Intangible Assets Investments ISS0.84 Loans 112.04 111.83 Others 13340.96 1 Deferred tax assets (net) 153.179 1 Other Non-Current Assets 1334.79 1 Total Non - Current Assets 1334.79 1 Current Assets 1334.79 1 Other Non-Current Assets 1334.79 1	Statucation Balance SHEET AS AT 31" March, 2020 (E In Lac) Asets Asets Image: Asets Non - Current Asets Asets Standalone Property, Plant and Equipment 0ther Intagible Asets 13340.95 Other Intagible Asets 13340.95 1 Investments 13340.95 1 Others 13340.95 1 Other Non-current Assets 13340.95 1 Deferred tax assets (net) 11.89 11.89 Other Non-current Assets 13347.79 1 Total Non - Current Assets 34117.37 34117.37			Financial Assets	
Kon - Current Assets Kar 31 ^m March, 2020	STANDALONE BALANCE SHEET AS AT 31 MARCH, 2020 C In Lacy Kin Lacy Assets As at 31 th March, 2020 K In Lacy Assets Standalone As at 31 th March, 2020 K In Lacy Assets Standalone Assets Property, Plant and Equipment 13340.95 Other Intangible Assets Investments 13340.95 Deferred tax assets (net) 1354.79 Other Non-current Assets 34117.37 Total Non - Current Assets 34117.37 <td></td> <td></td> <td>Current Assets</td>			Current Assets	
Kon Cont Lacy Cont Lacy Assets As at 31 ^m March, 2020 As at 31 ^m March, 2020 Non - Current Assets Standalone Property, Plant and Equipment 13340.95 Other Intangible Assets 13340.95 Investments 687.16 Investments 18860.94 Iorns 712.04 Others 1334.79	STAUCALIONE BALANCE SHEET AS AT 31" MARCH, 2020 (* In Lac) A sets Assets As at 31" March, 2020 (* In Lac) Assets Standalone 13340.96 Other Intangible Assets 13340.96 1 Investments 13340.96 1 Others 18850.84 1 Deferred tax assets (net) 1334.79 1	33640.51	34117/37	Utner Non-Current Assets	
Cit IdS) (Cit IdS) As at 31 ^m March, 2020 As at 31 ^m March, 2020 Assets Standalone Non - Current Assets 13340.96 Property, Plant and Equipment 13340.96 Other Intangible Assets 13340.96 Investments 13850.84 Loans 7112.04 Others 211.89	STANDALONE BALANCE SHEET AS AT 31 MARCH, 2020 C In Lacy Asets Asets In March, 2020 Asets Property, Plant and Equipment Other Intangible Assets 13340,96 13340,96 1 Investments 13340,96 1 1 Dons 13340,96 1 1 Other Intangible Assets 13340,96 1 1 Dons 11 11 1 Dons 11880,84 11 1 Others 11.89 11.89 1	412.07	1534.79	Deferred tax assets (net)	
Kini Lassy Kini Lassy As at 31 ^m March, 2020 As at 31 ^m March, 2020 Assets Standalone Non - Current Assets 13340.96 Property, Plant and Equipment 13340.96 Other Intangible Assets 13340.96 Financial Assets 13340.96 Investments 15880.84 10 10	STANDALONE BALANCE SHEEF AS AT 31 MARCH, 2020 (E In Lacs) Asets As at 31 ^m March, 2020 As at 31 ^m March, 2020 Asets Fronch, 2020 As at 31 ^m March, 2020 Mon - Current Asets Standalone Property, Plant and Equipment 13340,96 Other Intangible Asets 887.16 Investments 16860,84 1	210.08	211.89	(coans Others	
Kini Lasy Kini Lasy Asets As at 31 ⁿ March, 2020 As at 31 ⁿ March, 2020 Asets Image: Current Asets Standalone Non - Current Asets 13340.95 13340.95 Other Intangible Asets 13340.95 1 Financial Asets 687.16 1	Asets Non - Current Asets Property, Plant and Equipment Other Intangible Asets Financial Asets	16860.84 713.cc	16860.84	investments	
(f. In LaCs) (st. art 31 ^m March, 2020 As at 31 ^m March As at 31 ^m March Assets Non - Current Assets Property, Plant and Equipment 13340.96	STANDALONE BALANCE SHEET AS AT 31" MARCH, 2020 (7 in Lacs) As at 31" March, 2020 (7 in Lacs) Assets (8 assets (1 ass	906,43	687.16	Other Intangible Assets	
As at 31" March, 2020 (t in Lacs	STANDAIONE BALANCE SHEET AS AT 31" MARCH, 2020 (* In Lass As at 31" March, 2020 (* In Lass Assets	13768.85	13340.96	Non - Current Assets Property, Plant and Equipment	
K m Jacs As at 31 ^m March, 2020 Standalone	STANDALONE BALANCE SHEET AS AT 31" MARCH, 2020				
(K IN LEGS)	c in Iso		As at 31 March, 2020	Particulars	
		(SBEUS)	3		
			AIST LIMITED	ALCHEI	

Ì

International problem (1993) International problem (1993) <t< th=""><th></th><th>Place: New Delhi Date: 23:07.2020</th><th>Place Date:</th></t<>		Place: New Delhi Date: 23:07.2020	Place Date:
For its years ending Cf. It Loc) Star March, 2000 Star March, 2000 </th <th></th> <th></th> <th>*****</th>			*****
Cf in Lack Tor Tite years ending Tor Tite years 33st March, 2020 3st March, 2020 Star March, 2020 (4.672.78) 664.67 664.67 664.67 4,642.35 55.32 (4.672.78) (4.672.78) 664.67 (4.672.78) (4.672.78) 664.67 (4.672.78) (4.672.78) (4.672.78) (1.125.45) (4.60) (1.125.45) (1.125.45) (4.65.47) (1.55.46) (1.125.45) (1.15) (1.65.47) (1.65.47) (1.65.47) (1.65.47) (1.65.47) (1.65.47) (1.65.47) (1.15.15) (1.15.15) (1.15.15) (1.15.15) (1.15.15) (1.15.15) (1.15.15) (1.15.15) (1.15.15)			
Eor fits year ending For the year 315 March, 200 For the year 964.67 964.67 664.67 664.29 (4.072.78) 664.29 (4.072.78) 10.50 (1155.49) (48.07) (1155.49) (48.07) (1155.49) (48.07) (1151) (1153) (1153) (1153) (1151) (1153) (1151) (1153) (1151) (1153) (1152) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1153) (1154) (1153) (11552) (1153) (1153) (1153) (1154) (1153) (1155) (1153) (1155) (1153) (1153) (1153) (1153) (1153) (1153) (1	Cash and Cash Equivalents as at the end of the Year (refer Note) (151.52)	Cash and Cash Equi	T
For the year ending For the year 31st March, 2020 Sast March 664,67 4,644.28 (4,672,78) 655,26 (1,155,45) (4,605) (1,155,45) (4,85,07) (4,85,07) (4,85,07) (4,672,78) (55,26) (1,155,45) (4,605) (1,155,46) (4,637) (395,34) (1,157) (395,34) (1,157) (395,34) (1,157) (395,34) (1,157) (395,34) (1,157) (353,46) (1,157) (353,14) (35,14) (35,14) (35,14) (35,14) (35,14) (35,152) (35,14) (35,29) (33,29) (35,29) (33,29) (35,14) (35,29) (35,152) (35,14) (35,152) (35,14) (35,152) (35,14) (35,152) (35,14) (35,152) (35,14) (35,152)	Add: Cash and Cash Equivalents as at the Beginning of the Year (195,54)	Add: Cash and Cash	
For the year ending For the year ending For the year 3st March, 200 (4,572,78) 664,67	Net Increase / (Decrease) in Cash and Cash Equivalents During the Year (A+B+C) 44.02	Net Increase / (Decr	
Copinal Contracting Contracting Contracting Contracting Contracting Contracting Social State	Net Cash Generated from Financing Activities (C)	Net Cash Generat	
For the year ending (2 in Lac) Soft (4, 220) s 5 or the year 3 st March, 2020 s (4, 672, 73) (4, 642, 25) (4, 605) bies 664, 67 (4, 642, 25) (4, 605) s 10, 50 (1, 12, 45) s 10, 50 (2, 0, 0) (1, 15) sets 63, 25, 43 (1, 15) sets (3, 97, 4)) bilities (1, 5) (1, 5) Equipment and Intangible Assets including (1, 5) (17, 5) (1, 5) Equipment taries and Associates (17, 5) (12, 95)	uding Premium	Redemption of Preference Shares incl Proceeds/ (Repayment) of Borrowings Interest Paid	
For the year ending C in lacs) 31st March, 2020 For the year 664.67 4,642.78 664.67 4,642.95 55.26 (4,672.78) 10.50 (1,155.45) (1,155.45) (4,38.07) 10.50 (7,01) (4,38.07) (395.34) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45) (1,155.45)	ancing Activities	C. Cash Flow from Financing Activities	
Corr the year ending Corr the year ending Corr the year so 31st March, 2020 31st March, 2020 31st March, 2020 shes (4.672.78) 664.67 31st March, 2020 shes (4.672.78) 664.67 31st March, 2020 shes (4.672.78) 664.67 31st March, 2020 stall (4.672.78) 664.67 31st March, 2020 stall (4.672.78) (4.642.28) 55.36 (1.125.40) stall (1.125.40) (1.125.40) (1.15) (1.15) (1.15) seets (35.54) (1.15) (1.5) (1.5) (1.5) (1.5) shilties (3.5.54) (1.5) (1.5) (1.5) (1.5) (1.5) sting Activities (A) (35.54) (1.5)	Net Cash Flow from/ (used in) Investing Activities (B) (12.95)	Net Cash Flow frc	
Circle Circle year ending Circle year so 31st March, 2020 544.29 55.25 54.40 55.25 54.40 55.25 54.40 55.25 54.40 55.25 54.40 55.40 55.40 55.40 55.45 55.45 55.45 55.45 55.54 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.55 55.55	Capital Expenditure on Property, Plant & Equipment and Intangible Assets including (17.5.1) Capital Advances (17.5.1) Proceeds from Sale of Property, Plant & Equipment (1.5.1) Proceeds (Payment) from Loan to Subsidiaries and Associates (2.5.1) Interest Received (2.5.1)	Capital Expenditur Capital Advances Proceeds from Sale Proceeds/ (Payment Interest Received	
For the year ending For the year 31st March, 2020 31st Ma	resting Activities	B. Cash Flow from Investing Activities	
For the year ending For the year 31st March, 2020 31st March, 2020 (4.672.78) 664.57 664.57 4.644.28 (4.672.78) (1.125.45) (1.125.46) (1.125.46) (1.125.46) (1.15) (55.46) (1.15) (395.54) (1.87)	Net Cash Flow from/ (used in) Operating Activities (A) (397.41)	Net Cash Flow fro	
For the year ending (7 in Lacs) 31st March, 2020 31st March, 2020 (4.672.78) 664.57 664.57 4.644.28 55.26 (4.05) (1.125.45) (1.15) (1.15) (1.15)	ncial Assets ncial Liabilities	Other Financial and Non-Fina Other Financial and Non-Fina Cash Generated from operations Income Tax Paid	
For the year ending (7 in Lass) 31st March, 2020 31st March, 2020 664.67 4 644.28 53.25 (4.05) (1.123.45) (4.38.07) 10.50 (7.01)	(115) (115)	Inventories Provisions	
For the year ending (* in Lacs) 50r the year of the year 31st March, 2020 64.67 4.644.28 55.26 (4.05) (1.125.45) (1.125.45)		Trade Receivable Trade Payable	
For the year ending (7 in Lacs) 51st March, 2020 31st March, 2020 64.57 64.57 4.644.28 53.26 (4.55) (1.125.45) (1.125.45) (4.57.75)	Adjustments for changes in working capital	Adjustments for ch	
For the year ending For the year ending For the year and the year ending For the year 31st March, 2020 31st March, 2020 31st March, 664.57 664.57 664.57 664.57 664.57 (4.05)	Tax Expenses Operating Profit Before Working Changes in Working Capital (1)125(45)	Tax Expenses Operating Profit Be	
For the year ending For the year ending For the year a structure of the year for th		Interest Income	
For the year ending (? in Lacs) S1st March, 2020 31st March, (4,612,78) 664,67	Acceivables	Allowance for De	~~~~~
For the year ending For the year ending For the year and a start March, 2020 Site March, 20		Adjustments for Depreciation and Amortisation	
For the year ending 31st March, 2020		Loss for the year	
(? in lacs)	Cash Flow from Operating Activities	A. Cash Flow from (
88 J	For the year ending 31ct March 2020	Particular	
STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDING 31ST MARCH 2020	STANDALONE STATEMENT OF CASH FLOW FOR THE YEAR ENDING 31ST MARCH, 2020		Π
A L C H E M I ST L I M I T E D CORPORATE IDENTITY NUMBER: 172200011988PLC192643	A L C H E M I ST L I M I T E D CORPORATE IDENTITY NUMBER: L72200DL1988PLC192643		*****

, ,

ANU AND ASSOCIATES CHARTERED ACCOUNTANTS

Independent Auditor's Report on Standalone Annual Financial Results of Alchemist Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF ALCHEMIST LIMITED

Qualified Opinion

We have audited the accompanying standalone annual financial results of Alchemist Limited for the year ended 31st March, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended) ("Listing Regulations"), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

In our opinion and to the best of our information and according to the explanations given to us, except for the effects of the matter described in the *Basis for Qualified Opinion* section of our report, these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the standalone net loss and other comprehensive income and other financial information for the year ended 31st March, 2020.

Basis for Qualified Opinion

a. Attention is invited to note no. 4 to the accompanying financial results which states that "The Company extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Company is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, still considering the principal of conservatism, the Company has made a provision for expected credit loss @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2019-20. Hence forth, the Company shall not be accounting for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/payment. Cumulatively, the provision for expected credit loss on such export receivables at ₹ 9,288.56 Lakhs".

Such export receivables are outstanding for more than three years as at the year-end date, provision @ 20% is made against such doubtful trade receivables. Since the actual realisation of such doubtful export receivable cannot be ascertained, we are unable to comment on the adequacy of the provision of excepted credit loss made by the Company.

The loss to that extent is under stated, the effect however could not be quantified.

Though, the Company admits that the export receivable is doubtful of recovery and has made partial provision on such export receivable, still such export receivable and related trade payable stand in the books, hence require recognition of unrealised foreign exchange gain/loss as per the provisions of Ind AS 21, The Effects of Changes in Foreign Exchange Rates. Accordingly, the loss is overstated by ₹ 3,178.87 Lakhs for the year ended 31^{st} March, 2020 and accordingly the trade receivables and trade payable are understated by ₹ 4,329.75 Lakhs and ₹ 1150.88 Lakhs respectively, as at the year ended 31^{st} March, 2020.

b. Attention is invited to note no. 5 to the accompanying financial results which states that "The working capital limits of ₹ 350.00 Lakhs availed from Bank of India for the working capital requirements of the pharmaceutical division has been classified as non-performing asset (herein referred to as 'NPA') on 30th November, 2018. The outstanding as on the date of classification by the bank as NPA was ₹ 363.88 Lakhs. The Company has not recognised interest liability on such loan from the day it has become NPA, in line with the practice followed by the respective bank".

The Company has not made provision of interest due on the borrowings from Bank of India, post the date the account was classified as non-performing assets by the bank.

In the absence of the information on record, the consequential impact, if any, on the standalone financial results is not ascertainable.

c. The capital advances of ₹ 769.70 Lakhs are outstanding for more than three years as at the yearend date and seems doubtful of recovery or adjustment, however, no provision is made against such doubtful capital advances.

In the absence of the information on record, the consequential impact, if any, on the standalone financial statements is not ascertainable.

d. FDR's, current accounts and cash credit limit with a cumulative debit balance of ₹ 106.39 Lakhs and cumulative credit balance of ₹ 375.07 Lakhs could not be verified from statements or even balance confirmation.

In the absence of the information on record, the consequential impact, if any, on the standalone financial statements is not ascertainable.

e. The financial impact arising out of the COVID -19 outbreak are not accounted or reported or disclosed as per the prescribed Accounting Standards, in the financial statements.

In the absence of the information on record, the consequential impact, if any, on the standalone financial statements is not ascertainable.

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

Emphasis of Matters

- Attention is invited to note no. 6 of the accompanying financial results which states a. that "The accumulated losses of the Company had exceeded its net worth. The company's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Company has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Company has recently even closed down its loss making pharmaceutical manufacturing. The units of the company now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that accumulated losses would reasonably be paired, in due course. The Company can even liquidate its non-core strong fixed assets cover to support the operations in times of any need. Further, the Company has the backing of the strong group because of which the Company has been able to pay off its borrowings from Punjab National Bank and support the operations of the Company even though the Company has incurred losses in the recent past. The financial statements, as such have been prepared on a going concern basis".
- b. Attention is invited to note no. 7 of the accompanying financial results which states that "The income tax department has through its order dated 7th February, 2019 has demanded an amount of ₹ 29,129.34 Lakhs in lieu of the assessment carried out by the income tax departments for the assessments years 2009-10 to 2015-16. The Company has not provided for such liability in its books as it has appealed against such demand raised by the income tax department. The liability however, has been reflected as a contingent liability".

Our opinion is not qualified in respect of the matters as stated in the Emphasis of Matters paragraph.

Management's Responsibilities for the Standalone Financial Results

These standalone annual financial results financial results have been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the financial results for the quarter ended 31st March, 2020, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

for Anu and Associates Chartered Accountants ICAI Firm registration Number 019624N



Digitally signed by PARVEEN KUMAR Date: 2020.07.30 18:06:08 +05'30'

CA. Parveen Kumar *FCA., Partner* Membership Number 531655 **UDIN:** 20531655AAAADN4576

Place: New Delhi Date: 30th July ,2020

540,783 55.26 55.26 664.67 380.60 7288.48 (5798.41) (3798.41) (3798.41) (11125.45) (11125.45) (4672.26) (4672.26) (4672.27) (4655.18) (4655.18) (4655.28) (4655.28) (4655.28) (4655.28) (4655.28) (1135.598 7.78 (4652.37) (4652.37) (34.46)	(319.23) 0.00 0.00 (319.23) (172.14) (1		a) Current Tax. b) Deferred Tax. b) Deferred Tax. c) Profit-fyl Lass(-) for the period (8-9) c) Other Comprehensive income. items that will not be reclassified to profit or lass Re-measurement of the net defined benefit plans Tax on above Total Other comprehensive income, net of tax. I Total Other comprehensive income, net of tax. I Total Other comprehensive income, net of tax. I Total Other comprehensive income, for the period L Lass for the Year Attributed to Owners of The Parent Non-Controlling Interests Paid up equity share capital (Face Value of T 10/- each per share (EPS) after Extra Ordinary Items Basic and diuted Earning Value (EPS) after Extra Ordinary Items	8 9 9 11 11 12 13 13 13 14 14 14 15
1 540.78 552.26 664.67 1 46441.28 1 46441.28 1 (57798.41) 1 (57798.41) 1 (57798.41) 1 (57798.41) 1 (57798.41) 1 (46772.96) (46772.96) (46772.87) (4655.18) (4655.18) (4655.18) (4655.28) 1.355.98	(319.23) 0.00 (319.23) (319.23) (172.14			8 9 9 10 11 11 11 11 11 11 11 11 11 11 11 11
55,2,6 55,2,6 664,57 1 4,644,2,8 1 4,644,2,8 1 (57,98,41) 1 (57,98,41) 1 (57,98,41) 1 (11,25,45) 1 (45,72,95) 1 (45,72,95) 1 (45,72,87) 1 (45,72,87) 1 (45,72,87) 1 (45,72,87) 1 (45,72,87) 1 (13,55,98	(319.23) 0.00 (319.23) (319.23) (172.14			17 15 15 15 17
1 540.73 55.26 664.67 380.60 7380.88 1 (57986.43) (57986.43) (57986.4	(319.23) 0.00 (319.23) (319.23) (319.23) (177.14) (177.14) (177.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.29)			16 15 16 16 16 16 16 16 16 16 16 16 16 16 16
1 540.78 552.26 664.67 1 4544.28 380.60 7268.88 1 (5798.41) 1 (5798.41) 1 (1125.45) 1 (4672.26] 1 (4672.87) (4652.19) (4652.19) 1355.98	(319.23) 0.00 (319.23) (319.23) (172.14) (172.14) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09) (147.09)			10 10 9 8 8 10 11 10 10 10 10 10 10 10 10 10 10 10
540.73 540.73 55.26 664.57 380.60 7268.88 (5798.41) (5798.41) (5798.41) (5798.41) (1125.45) (4572.96) (4572.96) (4572.96) (4572.87) (4652.19) (4652.19) (4652.87)	(319.23) 0.00 (319.23) (319.23) (177.14) (177.14) (177.14) (177.06) 0.00 0.00 (147.06) (147.06) (147.06) (0.03)	. (4970.15) 		8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
540.78 552.26 664.57	(319.23) 0.00 (319.23) (319.23) (172.14) (9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
540.73 540.73 55.26 664.57	(319.23) 0.00 (319.23) (319.23)	(50.0) (50.0) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.2466) (50.24666) (50.246666) (50.24666666) (50.24666666666666666666666666666666666666		9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
540,78 552,26 664,67 380,60 7288,48 (5798,43) 0,00 (5798,41) (5798,41) (5798,41) (5798,41) (5798,41) (1125,45) (1125,45) (1125,45) (1125,45) (44672,96) (2,73) 7,78 (4465,18) (4465,18)	(319.23) 0.00 (319.23) (319.23) (319.23) (177.14) (177.14) (177.14) (177.15) (147.05) (147.05) (147.05)	(50.0) (20.6565)		9 8 8 112 112 112 112 112 112 112 112 112
540,78 55,26 664,67 - - - - - - - - - - - - - - - - - - -	(319.23) 0.00 (319.23) (319.23) (319.23) (172.14) (172.14) (172.14) (172.14) (172.14) (172.19) (147.09) (147.05)	(4970.15) (3976.29) (3976.29) (3976.29) (3976.29) (3976.29) (3976.29) (3976.29) (3976.29)	a) Cu 5) De Profit Other Items Total Total	10 9 8 10 10 10 10 10 10 10 10 10 10 10 10 10
540,78 552,26 664,67 380,60 728,64,88 (5798,643) 0,00 728,64 (5798,643) 0,00 (5798,643) (5798,643) (11125,45) (457,72,96) (457,72,96) (457,72,96) (4565,18)	(319.23) 0.00 (319.23) (172.14) (177.14) (147.09) 0.00 0.00 (147.09)	(10, 0596.) 2. (1, 02, 05, 05, 05, 05, 05, 05, 05, 05, 05, 05	a) Cur b) De Profit Otherns Items Total	14 11 10 9 8 8
540.78 552.26 664.67 - - - - - - - - - - - - - - - - - - -	(319.23) 0.00 (319.23) (172.14) (147.09) 0.00 0.00 (147.09)	(10 5855) 34. (34. (34. (34. (35. 29. (35. (35. 29. (35. (a) Cur b) De Profit Other Items Total	11 11 11 11 11
540.78 55.26 664.67	(1122.14) (1122.14)	(4970.15) (992.30) (9976.85) (9976.85) (10.51) (12.73) (2.73)	a) Cur b) De Profit Other Items	12 11 10 9 8
540.78 540.78 55.26 664.57 	(319.23) 0.00 (319.23) (172.14) (147.09) (147.09) 0.00	(4970.15) (9976.85)	a) Cur b) De Profit Others Items	10 9 8
540.723 540.723 55.26 664.57 	(319.23) 0.00 (319.23) (319.23) (172.14) (172.14) (147.09)	(4970.15)	a) Cur b) De Profit Other Items	11 10 9 8
540,78 540,78 55,26 664,67 7268,88 (5798,41) (5798,41) (5798,41) (5798,41) (1125,45)	(319.23) 0.00 (319.23) (319.23)	(4970.15)	a) Cur b) De Profit Other Items	9 9 11
540,78 552,26 664,67 - 4544,28 7268,38 (5798,41) - (5798,41) (5798,41) - (1125,45) (4677,296	(319.23) 0.00 (319.23) (319.23)	(4970.15) (993.30) (9975.85)		9 9 10
540,78 552,26 664,67 - - - - - - - - - - - - - - - - - - -	(319.23) 0.00 (319.23) (319.23)	(4970.15)		10 9 8
540,78 55,26 664,67 44544,28 380,60 728,8,28 (5798,41) 0,00	(319.23) 0.00 (319.23) (172.14)	(4970.15)		۵۵
5-40.78 5-40.78 664.67 	(319.23) 0.00 (319.23)	(4970.15)	a) Current Tax	۵۵
5-40.78 5-52.26 664.67 - - 4644.28 - - - - - - - - - - - - - - - - - - -	(319.23) 0.00 (319.23)	(4970.15)		۵ ۵
5-40.73 5-40.73 55.26 664.57 - - - 4644.28 380.60 7268.88 (5798.41) 0.00	(319.23) 0.00 (319.23)	(4970.15)	Tax Expenses	8
540.78 55.26 664.67 - - 4644.28 380.60 7268.88 (5798.41) 0.00	0.00 0.00		Profit Before Tax (5-6-7)	
5-40.78 5-5.26 664.67 - - 4644.28 380.60 7268.88 (5798.41) 0.00	(319.23) 0.00	0.00		7
5-40.78 5-52.56 664.67 - - - 4644.28 380.60 380.60 (5798.41)	(319.23)	0.00		6
540,78 55,26 664,67 - - 4644,28 - 380,60 7268,88		(4970.15)	Profit before Exceptional & Extraordinary Items (3-4)	s
540,78 55,278 664,67 	587.04	5118.81	Total Expenses	
540,78 540,78 664,67 	79.53	92.20	(ii) Other Expenditure other than (i) above	
540,78 55,256 664,67 -	0.00	4644.28	(ii) Provision for Expected Credit Loss	
540,78 55,26 664,67	•	•	Foreign Exchange (Gain)/Loss	
540.78 55.26 664.67			g) Other Expenditure	
540.78 55.26	166.84	162.56	f) Depreciation & Amortisation	
540.78	18.85	15.06	e) Finance costs	
	130.68	109.87	d) Employees benefit expenses	
30 05	6.91	1.60	c) (Increase)/decrease in stock in trade, finished goods and scrap	
481.28	87.39	11.90	b) Purchase of stock in trade	
229.17 469.07 847.60	96.84	81.34	a) Consumption of Raw Material & Others	
				4
1470.47 27	267.81	148.65		з
	3.71	20.14		2
571.69 1441.17 2673.60	264.11	128.52	Net Sales (Net of Excise Duty) / Incomes from Operations	1-4
(Refer Note Z) (Audited) (Audited)	(Unaudited) ((Refer Note 2)		
31.03.2019 31.03.20 31.03.19	31.12.2019	31.03.2020		
Year Ended	Quarter Ended			
			Particulars	S,No
3ED 31.03.2020	OR THE QUARTER AND YEAR END!	TED FINANCIAL RESULTS FO	PART I: STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2020	
		200000, 1 U.Y. (2 T. T.) 100000		
n. Website: www.alchemist.co.in	ew Dechi-110 019 88. E-mail: info@alchemist.co.in.	500300. Fax: (91-11) 40600	CN NO. 4722000 1988PLC192643. Tel No (9-11) 40500800. Fax: (9-11) 40500883. E-mail: info@alithemist.co.in. Website: www.alchemist.co.in	

, , ;

O

				5	 -			4 S				3			0	1		-								2						r i		S.No.			
Total	b) Agri Business	a) Pharma, Chemical & Minerais	(Segment assets-Segment Liabilities)	Capital Employed	Total Liabilities	b) Agri Business	a) Pharma, Chemical & Minerals	Segment Liabilities	Total Assets	b) Agri Business	a) Pharma, Chemical & Minerals	Segment Assets		Total Profit after Tax	Current and Deferred Tax	Total Profit before Tax	Less: Share of loss in Associate	Less:Unallocated expense of Subsidiary	Less: Exceptional Item	Add: Other Incomes	ess: Financial Charges	Total	b) Agri Business	a) Pharma, Chemical & Minerals	Profit/(Loss) before tax and interest from segments)	Segment Results	Net Sales/Incomes	Less Inter Segment Revenue	Sub-Yotal	b} Agri Business	a) Pharma, Chemical & Minerals	Segment Revenue (Net)		Particulars			0.2C (1) IVAJ
24914.78	787.27	24127.51			 14849.25	142.49	14705.76		 39764.03	929.76	38834.27			(3975.85)	(052.566)	(4970.15)	1	0,12		20,14	15.05	(4975.11)	69.26	(5044.37)			128.52		128.52	127.82	0.70		31.03.2020				PART II: SEGMENT INFORMATION FOR THE QUARTER AND TEAR ENDED 31.03.2020
29682.04	752.12	28929.92			14975.14	156.69	14818.45		44657.18	908.81	43748.37		-	(147.09)	(172.14)	(319.22)		. 0.05	ŀ	3.71	18.85	[304.03]	(95.27)	(208.76)			264.12	-	264,12	143.10	121.01		31.12.2019	Quarter Ended			R AND TEAR ENDED 31.0
29873.50	799.95	29073.55			14765.01	159.11	14605.91		44638.51	959.06	43679.46			742.64	(1177.36)	(434.71)		0.24	•	9.14	29.88	(413.73)	64.04	(477.77)			571.69		571.69	267.61	304.09		31.03.2019		CONSOLIDATED		3.2020
24914.78	787.27	24127.51			 14849.25	142.49	14706.76		 39764.03	929.76	38834.27			(4672.96)	(1125.45)	(5798.41)	-	0.18	•	29.30	55.26	(5772.27)	(209.86)	(\$\$62,41)			1441.17	4	1441.17	699.01	742.16		31.03.20	Yea			
29873.50	799.95	29073.55			14765.01	159.11	14605.91		44638.51	90.656	43679,46			(4964.34)	(1096.21)	(6060.55)	(0.50)	0.08		81.76	136.91	(6015.24)	(242.99)	(5772.25)			2673.60		2573.60	1122.03	1551.58		31.03.19	Year Ended		₹intacs)	

•

• •

B

	Date:
	Place: New Delhi
By Order of Board For Alchemist Umited	
The Group has not carried out the impact assessment study that COVID-19 may have on its operations and financials.	8
The income tax department has through its order dated 7th February, 2019 has demanded an amount of '29,129.34 Lakits in lieu of the assessment carried out by the income tax departments for the assessments years 2009-10 to 2015-16. The Group has not provided for such liability in its books as it has appealed against such demand raised by the income tax department. The liability however, has been reflected as a contingent liability.	E.
Interest Depreciation Tax and Amortization (EBIDTA). With strong management focus on strategic initiatives for cost rationalization, optimum product mix and efficient plant operations, the management believes that excumulated losses would reasonably be paired, in due course. The Group has the believes that in non-core strong fixed asserts cover to support the operations in times of any need. Further, the Group has the believes that the strong conglomerate because of which the Group has been able to pay off its borrowings fram Punjab National Bank and support the operations of the Group has the Group has into recent the strong conglomerate because of which the Group has been able to pay off its borrowings fram Punjab National Bank and support the operations of the Group have though the Group has incurred losses in the recent past. The financial statements, as such have been prepared on a going concern basis.	
The accumulated losses of the group had exceeded its net worth. The Parent's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Parent has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Parent during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the Parent now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before	8
The working capital limits of ₹ 350.00 Lakks availed from Bank of India for the working capital requirements of the pharmaceutical division has been classified as non performing asset (herein referred to as 'NPA') on 30th November, 2018. The outstanding as on the date of classification by the bank as NPA was Rs. ₹ 363.88 Lakhs. The Group has not recognised interest liability on such loan from the day it has become NPA, in line with the practice followed by the respective bank.	S
The Group extends credit from time to time as per market practices. In respect of export receivables amounting to X 46,442.79 takis, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Group is regularly following up on the same, initiate deglar recourse and is hopeful of recovering such amount, stil considering the principal of conservatism, the Group has made a provision for expected credit loss allowance @ 10% of the outstanding export receivables amounting to X 46,44.28 takhs and has not recognised unrealised foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2019-20. Hence forth, the Group shall not be accounting for the unrealised foreign exchange loss on such export receivables and the same will related trade payable during the financial year 2019-20. Hence forth, the Group shall not be accounting for the unrealised foreign exchange loss on such export receivables and the same will only be accounted for on actual realisation/ payment. Cumulatively, the provision for expected credit loss on such export receivables stands at X 9,288.56 takhs.	.
The figures for the previous period have been regrouped/reclassified, wherever necessary to conform to the current period's presentation.	3)
The figure for the quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figure of the years ended 31st March, 2020 and 31st March, 2019 respectively and published financial results of nine months ended 31st December, 2019 and 31st December, 2018 respectively.	2)
The above consolidated financial results, as reviewed by Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on 28th July, 2020. The Statutory Auditors have expressed modified opinion on these results.	1)

D

Provide the second s	Place New Delhi Date: 3807.2020	Property, Plant and Equipment 5330.55 Other Interglish Assets 587.15 Finandi Assets 587.15 Finandi Assets 587.15 Investment 571.19 Investment 571.20 <th>Particulars As at 31^{rr} March, 2020 Particulars Assets Non - Current Assets</th>	Particulars As at 31 ^{rr} March, 2020 Particulars Assets Non - Current Assets
---	------------------------------------	---	--

G

For Alchemist Limited		Place: New Delhi	Place: New Delhi
of Boa			
(195.12)	(151,41)	Cash and Cash Equivalents as at the end of the Year (refer Note 13)	
(117,52)	(195,12)	Add: Cash and Cash Equivalents as at the Beginning of the Year	
(65.71)	+0.43,70	Net Increase / (Decrease) in Cash and Cash Equivalents During the Year (A+B+C)	
884.72	454,48	Net Cash Generated from Financing Activities (C)	
(2.50) 1.023.48 (136.27)	(16°29) 878'38	Redemption of Proference Shares including Premium Proceeds (Repayment) of Borrowings Interest Paid	
		Cash Flow from Financing Activities	0
2001 100 100 100 (292.26)	2011 - 12 - 22 - 22 - 22 - 22 - 22 - 22	Net Cash Flow from/ (used in) Investing Activities (B)	
8,41 2,82 2,82 2,82 2,82 2,82 2,82 2,82 2,8	140 (0.733) (0.51	Capital Expenditure on Property, Plant & Equipment and Intangible Assets inclu: Proceeds from Sale of Property, Plant & Equipment Proceeds/ (Payment) from Loan to Subsidiaries and associated Interest Received	
		Cash Flow from Investing Activities	ά
(670.03)	2010 (1726) (1720) (397,82)	Net Cash Flow from/ (used in) Operating Activities (A)	
103.06 (83.06) (669.80) (0.20)	(1.82) (1.82) (1.82)	Coher Financial and Non-Financial Assets Other Financial and Non-Financial Liabilities Cash Generated from operations Income Tax Paid	
82.67 (1.84)	49.84 17	Inventories	
(11) (11)	10.50	Adjustments for changes in working capital Trade Receivable	
(592,63)	(438.37)	Operating Profit Before Working Changes in Working Capital	
(3.82)	(4,05) (1,125,45)	Interest Income	
4,644.28	4,644.28	Allowance for Doubtful Trade Receivables	
650 61		Share in Upening Loss of Associate	
	(02.90) (02.91)	Loss for the year Adjustments for	
VY PUG 7	00 679 M 210	Cash Flow from Operating Activities	A
For the year ending 31st March, 2019	For the year ending 31st March, 2020	Particular	
دسده (۳ In Lacs)	FOR THE TERM EINDING STOL MISSION	CONSCIENTING OF AND	
ncec	CORPORATE IDENTITY NUMBER: UT22000L1988PLC192543	CONSULT OF A CONSULT	

.

D

.

an the

ANU AND ASSOCIATES CHARTERED ACCOUNTANTS

Independent Auditor's Report on Consolidated Financial Results of Alchemist Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

TO THE BOARD OF DIRECTORS OF ALCHEMIST LTD

Qualified Opinion

We have audited the accompanying consolidated annual financial results of Alchemist Limited ('the Parent'), its subsidiaries and associate (the Parent, its subsidiaries, and associate together referred to as 'the Group') for the year ended 31 March 2020, attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ("SEBI") from time to time.

In our opinion and to the best of our information and according to the explanations given to us except for the effects of the matter described in the *Basis for Qualified Opinion* section of our report, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiary and associate, the consolidated financial results:

- i. include the financial results for the year ended 31st March, 2020 of the following entities:
 - \checkmark Alchemist Limited,
 - ✓ Alchemist Healthcare Limited, and
 - ✓ Alchemist Medisphere Limited;
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net loss and other comprehensive income and other financial information for the year ended 31st March, 2020.

Basis for Qualified Opinion

a. It has been explained to us that the financial statements of one associate, ROC Foods Limited is still under compilation and one subsidiary viz. Alchemist Hospitality Group Limited is under strike off. Accordingly, the same are not forming part of the consolidated financial results. b. Attention is invited to note no. 4 to the accompanying consolidated financial results which states that "In respect of Alchemist Limited, "The Group extends credit from time to time as per market practices. In respect of export receivables amounting to ₹ 46,442.79 Lakhs, credit was extended for export sales in the normal course of the business, however it apparently got stuck. Though the Group is regularly following up on the same, has initiated legal recourse and is hopeful of recovering such amount, still considering the principal of conservatism, the Group has made a provision for expected credit loss allowance @ 10% of the outstanding export receivables amounting to ₹ 4,644.28 Lakhs and has not recognised unrealised foreign exchange gain/loss on such export receivable and related trade payable during the financial year 2019-20. Hence forth, the Group shall not be accounting for the unrealised foreign exchange loss on such export receivable and related trade payables and the same will only be accounted for on actual realisation/ payment. Cumulatively, the provision for expected credit loss on such export receivables stands at ₹ 9,288.56 Lakhs".

Such export receivables are outstanding for more than three years as at the yearend date; provision @ 20% is made against such doubtful trade receivables. Since the actual realisation of such doubtful export receivable cannot be ascertained, we are unable to comment on the adequacy of the provision of excepted credit loss made by the Group.

In the absence of the information on record, the consequential impact, if any, on the consolidated financial results is not ascertainable.

Though, the Group admits that the export receivable is doubtful of recovery and has made partial provision on such export receivable, still such export receivable and related trade payable stand in the books, hence require recognition of unrealised foreign exchange gain/loss as per the provisions of Ind AS 21, The Effects of Changes in Foreign Exchange Rates. Accordingly, the loss is overstated by ₹ 3,178.87 Lakhs for the year ended 31^{st} March, 2020 and accordingly the trade receivables and trade payable are understated by ₹ 4,329.75 Lakhs and ₹ 1150.88 Lakhs respectively, as at the year ended 31^{st} March, 2020.

c. Attention is invited to note no. 5 to the accompanying consolidated financial results which states that "The working capital limits of ₹ 350.00 Lakhs availed from Bank of India for the working capital requirements of the pharmaceutical division has been classified as non-performing asset (herein referred to as 'NPA') on 30th November, 2018. The outstanding as on the date of classification by the bank as NPA was ₹ 363.88 Lakhs. The Group has not recognised interest liability on such loan from the day it has become NPA, in line with the practice followed by the respective bank."

The Group has not made provision of interest due on the borrowings from Bank of India, post the date the account was classified as non-performing assets by the bank.

In the absence of the information on record, the consequential impact, if any, on the consolidated financial results is not ascertainable.

- d. The entire capital advances, capital advances of ₹ 769.70 Lakhs are outstanding for more than three years as at the yearend date and seems doubtful of recovery or adjustment, however, no provision is made against such doubtful capital advances. In the absence of the information on record, the consequential impact, if any, on the consolidated financial results is not ascertainable.
- e. FDR's, current accounts and cash credit limit with a cumulative debit balance of ₹106.39 Lakhs and cumulative credit balance of ₹375.07 Lakhs could not be verified from statements or even balance confirmation.
- In the absence of the information on record, the consequential impact, if any, on the standalone financial results is not ascertainable.
- f. The financial impact arising out of the COVID-19 outbreak are not accounted or reported or disclosed as per the prescribed Accounting Standards, in the consolidated financial results.

In the absence of the information on record, the consequential impact, if any, on the consolidated financial results is not ascertainable.

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, its associates and jointly controlled entities in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our qualified opinion.

Emphasis of Matters

a. Attention is invited to note no. 6 of the accompanying consolidated financial results which states that "The accumulated losses of the group had exceeded its net worth. The Parent's operations were adversely affected in earlier financial years due to sluggish market demand, working capital getting stuck in trade receivables and loss making manufacturing activity of the pharmaceutical unit. The Parent has initiated legal recourse against the defaulting customers and is regularly following up on the same and the Parent during the last year has even closed down its loss making pharmaceutical manufacturing. The units of the Parent now continue to operate at satisfactory capacity utilization levels and are generating positive Earnings before Interest Depreciation Tax and Amortization, optimum product mix and efficient plant

operations, the management believes that accumulated losses would reasonably be paired, in due course. The Group can even liquidate its non-core strong fixed assets cover to support the operations in times of any need. Further, the Group has the backing of the strong conglomerate because of which the Group has been able to pay off its borrowings from Punjab National Bank and support the operations of the Group even though the Group has incurred losses in the recent past. The financial statements, as such have been prepared on a going concern basis."

b. Attention is invited to note no. 7 of the accompanying financial results which states that "The income tax department has through its order dated 7th February, 2019 has demanded an amount of ₹ 29,129.34 Lakhs in lieu of the assessment carried out by the income tax departments for the assessments years 2009-10 to 2015-16. The Group has not provided for such liability in its books as it has appealed against such demand raised by the income tax department. The liability however, has been reflected as a contingent liability."

Our opinion is not qualified in respect of the matters as stated in the Emphasis of Matters paragraph.

Management's Responsibilities for the Consolidated Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual audited financial statements and has been approved by the Parent's Board of Directors.

The Parent's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the accounting principles generally accepted in India, including the Ind AS prescribed under section 133 of the Act, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Parent's Board of Directors of the companies included in the Group and of its associates are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and its associates and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Parent, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group and of its associates are responsible for assessing the ability of the Group and of its associates to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associates are responsible for overseeing the financial reporting process of the Group and of its associates.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and jointly controlled entities to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associates to express an opinion on the consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Parent and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

a. We did not audit the financial statements of Alchemist Healthcare Limited and Alchemist Medisphere Limited included in the consolidated financial results for the year ended 31st March, 2020. These financial statements have been audited by other auditors whose reports have been furnished to us, and our opinion on the financial results for the year ending 31st March, 2020, to the extent they have been derived from such financial statements is based solely on the reports of such other auditors. Our opinion is not modified in respect of this matter.

b. The Statement includes the consolidated financial results for the quarter ended 31st March 2020, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

for Anu and Associates Chartered Accountants ICAI Firm registration Number 019624N

PARVEEN KUMAR Digitally signed by PARVEEN KUMAR Date: 2020.07.30 18:26:18 +05'30'

CA. Parveen Kumar *FCA., Partner* Membership Number 531655 **UDIN: 20531655AAAADO6127**

Place: New Delhi Date: 30th July ,2020



Date: 30.07.2020

The Deputy Manager Department of Corporate Services Bombay Stock Exchange Limited (BSE) P.J. Towers, 25th Floor, Dalal Street, Fort Mumbai - 400001

The Manager (Listing Department) National Stock Exchange of India Limited (NSE) Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Scrip Code: 526707

Scrip Code: ALCHEM

Sub: - Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulation, 20 15

Dear Sir I Madam, Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015 and in compliance with SEBI Circular No. C!R/CFD/CMD/56/2016 dated 27th May, 2016, it is hereby declared an d confirmed that the Audit report in respect of Financial Statement for the year ended 31st March, 2020 issued' by M/s. Anu & Associates., Chartered Accountants, Statutory Auditors of the Company are with Qualified opinion.

Kindly take it on your record.

Thanking you

Yours Sincerely

For Alchemist Limited Divya Bajaj **Company Secretary**

ALCHEMIST LTD.

CIN: L72200DL1988PLC192643